Trial · NCT06513338
Complement C5 mAb in the Treatment of Anti-GBM Disease
NCT06513338, Phase 2, Completed, Peking University First Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Complement C5 mAb in the Treatment of Anti-GBM Disease. Trials, record NCT06513338. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06513338
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Complement C5 mAb in the Treatment of Anti-GBM Disease
- NCT number
- NCT06513338
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- Peking University First Hospital
- Conditions
- Autoimmune Diseases
- Interventions
- Eculizumab
- First posted
- 2024-07-22
- Last updated
- 2025-12-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | kidney prognosis | 6 months after the first infusion of eculizumab | ESKD (dialysis dependent) or kidney translation |
| Secondary | Changes in glomerular filtration rate (eGFR); | from baseline to study completion, an average of 1 year | Change in level of estimated Glomerular Filtration Rate (eGFR) as measured by laboratory testing, reported in mL/min/1.73m². |
| Secondary | Changes in serum creatinine | from baseline to study completion, an average of 1 year | Change in concentration of serum creatinine as measured by laboratory testing, reported in µmol/L |
| Secondary | Changes in blood urine nitrogen (BUN) | from baseline to study completion, an average of 1 year | Change in concentration of Blood Urea Nitrogen (BUN) as measured by laboratory testing, reported in mmol/L |
| Secondary | side effects of eculizumab | at 6 months | The number of participants experiencing any adverse events determined by the investigator to be related to eculizumab treatment. |
| Other | kidney function recovery | 6 months after the first eculizumab infusion | Kidney recovery was defined as independence from kidney replacement therapy (KRT, such as dialysis) lasting at least 12 weeks during follow-up |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06513338
GET https://conductscience.org/api/trials/v1/NCT06513338/registered